HIKALNSEHikal Limited· PharmaceuticalsHighNeutral
Announced Wed, 27 May · 16:07 IST

Hikal Limited has informed the Exchange that Board of Directors at its meeting held on May 27, 2026, recommended Final Dividend of Rs. 0.40 per equity share.

Pat NegativeExceptional ItemEmphasis Of MatterResults View source PDF

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-12.9%1-day move
₹220.99
prior close
₹209.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.2-1.9-2.0-2.9-12.9-13.2-14.8-13.3-14.4-17.8-7.0-3.1
Up moveDown movePending
AI summary

Hikal Limited reported a net loss of Rs. 487 million for FY 2025-26, a sharp decline from profit of Rs. 909 million in the previous year. Revenue from operations fell to Rs. 17,126 million from Rs. 18,598 million, driven by USFDA warning letter impact on Pharma segment sales. The company recorded exceptional items totaling Rs. 851 million, including Rs. 471 million impairment charge for plant repurposing and Rs. 380 million due to new labour code implementation. The Board recommended final dividend of Rs. 0.40 per share (20%), bringing total dividend for the year to Rs. 0.60 per share (30%), significantly lower than previous year's Rs. 1.40 per share (70%). Auditors issued an unmodified opinion but drew attention to an environmental compliance matter pending before the Supreme Court. Operating cash flow remained healthy at Rs. 3,021 million.

Likely market impact

The company swung to a loss due to exceptional items and revenue decline, raising concerns about profitability. The sharply reduced dividend (down 57% from last year) signals financial stress. However, positive operating cash flow and unmodified audit opinion provide some comfort about the company's ability to continue as a going concern.